对普拉拉特雷克萨特单剂研究的综合分析,对患有复发性/耐药性外围T细胞淋巴瘤的患者进行
Owen A O'Connor1, Bor-Sheng Ko2,3, Ming-Chung Wang4
1Division of Hematology-Oncology, University of Virginia Comprehensive Cancer Center, Translational Orphan Blood Cancer Research Center, University of Virginia, Charlottesville, VA.
Blood advances
|March 1, 2024
概括
普拉特雷克萨特在复发或耐药的外围T细胞淋巴瘤 (PTCL) 中显示出有效性,反应率为40.7%. 需要进一步的研究来证实这一T细胞淋巴瘤治疗的亚组发现.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 复发性或耐火性 (R/R) 成熟的自然杀手细胞和T细胞淋巴瘤具有有限的治疗选择.
- 周围T细胞淋巴瘤 (PTCL) 包含了一组异质的侵袭性非霍奇金淋巴瘤.
研究的目的:
- 评估普拉拉特雷克萨特在R/R PTCL患者的安全性和有效性.
- 确定影响这种患者群体中普拉拉特雷克萨特治疗结果的因素.
主要方法:
- 来自四项前性,监管授权的临床试验的数据的综合分析.
- 包括221名患有R/R PTCL的患者,包括像PTCL-NOS,血管免疫细胞T细胞淋巴瘤和ALK阴性形大细胞淋巴瘤 (ALCL) 这样的亚型.
主要成果:
- 观察到,用pralatrexate的客观反应率为40.7%.
- 响应的中位持续时间为9.1个月,无进展生存时间为4.6个月,总生存时间为16.3个月.
- 常见的不良事件包括口腔炎,血小板衰竭和白血病衰竭.
结论:
- 聚合分析结果支持使用普拉拉特雷克萨特治疗R/R PTCL.
- 探索性亚组分析表明基于先前的治疗线和淋巴瘤亚型的潜在疗效差异.
- 需要进一步的前性研究来验证子组发现.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
87
相关概念视频
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
897
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
